Dr Reddys Laboratories logo

Dr Reddys Laboratories

DRREDDY NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
₹95,419 Cr
Volatility
Moderate
P/E Ratio
30.19
EBITDA
₹7,812 Cr
Return on Equity
10.87%
Debt to Equity
0.2
Book Value
₹456.14
EPS
₹333.59
52W High
₹1,414.9
52W Low
₹1,101

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company's working capital requirements have reduced from 85.1 days to 67.8 days

Weaknesses

1
  • Dividend payout has been low at 13.2% of profits over last 3 years

Growth Rate

Revenue Growth
3.9% lower than 3Y
Net Income Growth
-27.38% lower than 3Y
Cash Flow Change
22.2% lower than 3Y
ROE
-35.57% lower than 3Y
ROCE
-36.29% higher than 3Y
EBITDA Margin (Avg.)
-22.04% higher than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk medium

Dr Reddy's Laboratories, with a market cap of ₹95,419 Cr and a P/E of 29.9x, is navigating a challenging near-term period marked by a TTM sales decline of -1% and a sharp -43% TTM profit decline, contrasting with a solid 5-year compounded sales growth of 12% and profit CAGR of 15% over the same horizon.

Bull Case 7
  • Strong 5-year compounded sales growth of 12% demonstrates consistent top-line expansion over a medium-term horizon
  • 5-year compounded profit growth of 15% indicates the company has delivered meaningful earnings growth over a longer cycle despite recent weakness
  • Working capital efficiency has improved significantly, with requirements reducing from 85.1 days to 67.8 days, freeing up cash for operations and investment
  • 10-year compounded sales growth of 8% reflects a durable, long-term revenue growth track record across market cycles
  • 3-year ROE of 16% and 5-year ROE of 16% show the company has historically generated healthy returns on shareholder equity
  • Price-to-book ratio of 2.5x is relatively moderate for a large-cap pharma name, suggesting the stock is not excessively valued on a book value basis
  • 10-year stock CAGR of 6% shows the company has delivered positive long-term shareholder returns despite recent underperformance
Bear Case 8
  • TTM compounded profit has declined -43%, signalling a severe near-term earnings contraction
  • TTM compounded sales growth is -1%, indicating the top line has stalled or slightly contracted in the most recent period
  • Last year ROE dropped to 11% from a 3-year average of 16%, reflecting a meaningful deterioration in return on equity
  • 1-year stock CAGR of -12% shows significant recent share price underperformance and negative sentiment
  • Dividend payout has been low at just 13.2% of profits over the last 3 years, limiting direct cash returns to shareholders
  • Dividend yield stands at only 0.7%, offering minimal income support to investors
  • 3-year compounded profit growth is -4%, suggesting earnings have struggled to grow even over a multi-year window
  • P/E of 29.9x appears elevated relative to the current earnings trajectory of declining profits, raising questions about valuation sustainability

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Neutral 1
  • Investor meetings in September Sep 10

    Dr Reddys scheduled analyst/investor meetings on Sep 17 (in-person with ICICI Securities) and Sep 24 (virtual with Bank of America), 2026.

TL;DR: Limited news flow for Dr Reddys this period, with only routine investor engagement scheduled. No material headwinds or positive catalysts emerged. The upcoming meetings with ICICI Securities and Bank of America may provide forward guidance, so watch for any commentary on pipeline or earnings outlook.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
6,758
6,903
7,237
7,114
7,696
8,038
8,381
8,528
8,572
8,828
8,753
7,546
8,100
Expenses
4,696
4,894
5,214
5,283
5,566
5,962
6,108
6,530
6,398
6,818
6,866
7,164
7,240
Operating Profit
2,062
2,008
2,023
1,831
2,130
2,076
2,273
1,998
2,174
2,010
1,888
382
860
OPM %
31%
29%
28%
26%
28%
26%
27%
23%
25%
23%
22%
5%
11%
Other Income
178
319
219
201
193
314
154
528
290
330
271
480
356
Interest
37
35
39
59
60
76
82
66
83
91
94
106
126
Depreciation
353
376
374
368
381
397
471
455
476
505
521
557
537
PBT
1,850
1,917
1,829
1,605
1,883
1,917
1,874
2,005
1,905
1,745
1,543
200
553
Tax %
24%
23%
24%
18%
26%
30%
25%
21%
26%
23%
23%
-11%
21%
Net Profit
1,405
1,482
1,381
1,310
1,392
1,342
1,404
1,587
1,410
1,337
1,190
221
436
EPS in Rs
16.87
17.77
16.56
15.7
16.69
15.05
16.94
19.09
16.99
16.14
14.5
2.65
5.32
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
15,023
15,568
14,196
14,281
15,448
17,517
19,048
21,545
24,670
28,011
32,644
33,700
33,228
Expenses
11,515
11,983
11,724
11,930
12,270
15,040
15,173
17,778
18,200
20,078
24,097
27,247
28,088
Operating Profit
3,508
3,585
2,472
2,351
3,178
2,477
3,874
3,768
6,470
7,933
8,547
6,454
5,140
OPM %
23%
23%
17%
16%
21%
14%
20%
17%
26%
28%
26%
19%
15%
Other Income
260
295
172
155
381
670
335
555
971
909
1,119
1,372
1,437
Interest
108
83
63
79
89
98
97
96
143
171
283
374
416
Depreciation
760
939
1,027
1,077
1,135
1,163
1,229
1,165
1,250
1,470
1,704
2,059
2,119
PBT
2,900
2,859
1,554
1,350
2,336
1,886
2,884
3,061
6,048
7,201
7,680
5,393
4,041
Tax %
19%
26%
19%
32%
17%
-7%
32%
29%
25%
23%
25%
23%
—
Net Profit
2,336
2,131
1,292
947
1,950
2,026
1,952
2,182
4,507
5,578
5,725
4,158
3,183
EPS in Rs
27.43
24.98
15.59
11.41
23.49
24.38
23.47
26.23
54.14
66.87
67.77
50.27
38.61
Div. Payout %
15%
16%
26%
35%
17%
21%
21%
23%
15%
12%
12%
16%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
85
85
83
83
83
83
83
83
83
83
83
84
Reserves
9,768
12,484
12,179
12,489
13,941
15,516
17,558
19,129
23,203
28,171
33,466
37,808
Borrowings
4,314
3,352
4,918
5,071
3,838
2,210
3,031
3,384
1,347
2,002
4,677
7,734
Other Liabilities
4,290
4,408
4,474
4,706
4,557
5,414
5,915
7,149
7,576
8,523
9,797
10,951
Total Liabilities
18,457
20,330
21,654
22,349
22,418
23,223
26,588
29,746
32,209
38,780
48,023
56,577
Fixed Assets
5,377
6,563
6,931
6,968
7,191
6,850
8,206
8,122
9,219
10,426
18,226
22,063
CWIP
529
772
3,324
3,470
2,934
1,535
1,565
1,293
1,030
1,419
2,466
1,460
Investments
2,248
3,833
2,110
2,298
2,587
2,678
2,212
2,616
4,986
4,930
4,051
5,285
Other Assets
10,303
9,162
9,290
9,612
9,707
12,160
14,605
17,715
16,974
22,004
23,280
27,768
Total Assets
18,457
20,330
21,654
22,349
22,418
23,223
26,588
29,746
32,209
38,780
48,023
56,577
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
2,524
3,263
2,144
1,803
2,870
2,984
3,570
2,811
5,888
4,543
4,643
5,674
Investing
-2,370
-1,610
-1,890
-1,483
-769
-495
-2,255
-2,565
-4,109
-4,034
-5,785
-6,425
Financing
-433
-1,700
-369
-444
-2,133
-2,516
-30
-242
-2,686
-376
1,891
829
Net Cash Flow
-280
-47
-114
-124
-31
-27
1,286
3
-907
133
749
78
Free Cash Flow
1,009
2,065
926
713
2,248
2,412
2,323
1,238
4,009
1,908
1,327
2,004
CFO/OP
88
111
110
88
106
149
107
94
108
83
78
109
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
100
97
98
104
94
105
95
113
107
105
101
110
Inventory Days
248
248
282
263
273
230
273
250
232
283
260
228
Days Payable
84
88
104
121
111
100
109
111
108
116
97
91
Cash Conversion Cycle
264
257
275
246
256
235
259
252
231
271
264
247
Working Capital Days
26
34
-14
39
65
59
57
61
84
118
69
68
ROCE %
22%
19%
9%
8%
13%
11%
16%
14%
27%
27%
23%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Dr Reddys Laboratories insights

70 extracted metrics + investor summaries across FY09–FY27.

Log in — free

Shareholding Pattern

FIIs32.07%DIIs31.74%Others2.13%Public7.42%Promot.26.64%As ofJun 2026

Documents

Frequently Asked Questions about Dr Reddys Laboratories

What does Dr Reddys Laboratories Ltd do?
Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
Where is Dr Reddys Laboratories Ltd (DRREDDY) listed?
Dr Reddys Laboratories Ltd trades as DRREDDY on the NSE and under code 500124 on the BSE.
Which sector does Dr Reddys Laboratories Ltd belong to?
Dr Reddys Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd has a market capitalisation of ₹95,419 Cr, which places it in the Large Cap band.
What is the PE ratio of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd trades at a PE ratio of 30.19, on earnings per share of ₹333.59, against a book value of ₹456.14 per share.
What is the 52-week high and low of Dr Reddys Laboratories Ltd?
Over the last 52 weeks Dr Reddys Laboratories Ltd has traded between ₹1,101 and ₹1,414.9.
Does Dr Reddys Laboratories Ltd pay dividends?
Dr Reddys Laboratories Ltd has a dividend yield of 0.70%.
What is the Return on Equity (ROE) of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd reported a return on equity of 10.87%. Its debt-to-equity ratio is 0.20.

Company Information

Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.

Website drreddys.com
CEO Mr. Gunupati Venkateswara Prasad B.E.
Employees 27,811
Listed 2003-05-30
Face Value ₹ 1
Issued Size 83,46,30,355

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/DRREDDY.md for Dr Reddys Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List